Article Sidebar

PDF (Tiếng Việt)
Published: 2024-07-31
Abstract Views: 39
Views PDF (Tiếng Việt): 37
DOI: https://doi.org/10.52852/tcncyh.v179i6.2507
Issue
Vol. 179 No. 6 (2024)
Section
Các bài báo
How to Cite
Tùng, N. T., & Hiếu, N. V. (2024). 22. Evaluating the results of concurrent chemoradiotherapy using vmat technique for lower middle esophageal cancer. Journal of Medical Research, 179(6), 207-217. https://doi.org/10.52852/tcncyh.v179i6.2507

22. Evaluating the results of concurrent chemoradiotherapy using vmat technique for lower middle esophageal cancer

Nguyen Thanh Tung, Nguyen Van Hieu

Main Article Content

Abstract

The study describes the outcomes of concurrent chemoradiotherapy using VMAT technique in 78 patients with squamous cell carcinoma of the mid-to-lower esophagus, stage II-IVA, treated at Vietnam National cancer hospital from January 2022 to December 2023. The aim was to depict clinical and paraclinical characteristics, assess treatment response, dose parameters, and toxicity of this protocol. The average age was 56.5 ± 5.9 years, with the majority in stage III. The overall response rate after radiotherapy was 34.2%. Dosimetric parameters such as D2, D98, and V95 dose coverage (93.96 - 98.20%) as well as V105% overdose (4.7 - 10.2%) of the VMAT technique were greater than other methods. Doses to ORAS were below recommended levels. 26 patients underwent surgery after radiotherapy, with 100% achieving R0 resection. Histopathological response post-surgery showed a better result comparing to other methods. Hematological, pulmonary, and dermatological toxicities were mild, with no cardiac complication. Concurrent chemoradiotherapy using VMAT technique demonstrated good outcomes and mild toxicity.

Article Details

Keywords

Esophagus Cancer, Concurrent chemoradiotherapy, Volumetric modulated arc therapy (VMAT)

References

1. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
2. Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015; 12:1–30.
3. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD. Blum M, et al. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014; 21: 306–14.
4. Munch S, Alchmeier S, Hapfelmeir A, Duma MN, Oechsner M, Felth M, et al. Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT. Strahlenther Onkol. 2016; 192: 722–9.
5. Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011; 84: 967–96.
6. Franco P, Arcadipane F, Ragona R, Mistrangelo M, Cassoni P, Munoz F, et al. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. Br J Radiol.2016; 89(1060): 20150832.
7. Iorio GC, Franco P, Gallio E, Martini S, Arcadipane F, BartonciniS, et al. Volumetric modulated arc therapy (VMAT) to deliver nodal irradiation in breast cancer patients. Med Oncol. 2018; 35: 1.
8. Radiation Therapy Oncology Group. Acute radiation morbidity scoring criteria. http://www.rtog.org. Accessed August 22 2018.
9. National Cancer Institute Cancer Therapy Evaluation Program. Common Toxiity Criteria for Adverse Events. Version 4.02. http://ctep.cance r.gov. Accessed August 22 2018.
10. Hàn Thanh Bình, Nhận xét đặc điểm lâm sàng, mô bệnh học và kết quả điều trị ung thư biểu mô thực quản tại bệnh viện K giai đoạn 1998 - 2004, Luận văn Bác sĩ nội trú, 2004, Đại học Y Hà Nội.
11. Nguyễn Đức Lợi, Đánh giá hiệu quả phác đồ hóa xạ trị đồng thời và một số yếu tố tiên lượng ung thư biểu mô thực quản giai đoạn III- IV tại Bệnh viện K. Luận văn tiến sĩ y học, 2015. Trường Đại học Y Hà Nội.
12. Hurmuzlu M, Monge O et al, “High-dose definitive concomitant chemoradiotherapy in non- metastatic advanced esophageal cancer: toxicity and outcome “. Diseases of the Esophagus. 2010; 23: 244-252.
13. J S, Jjb van L, Mccm H, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet. Oncology. doi:10.1016/S1470-2045(15)00040-6.
14. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26(7): 1086-1092. doi:10.1200/JCO.2007.12.9593.
15. De Vita F, Di Martino N, Orditura M, et al. Preoperative Chemoradiotherapy for Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: A Phase II Study. Chest. 2002; 122(4): 1302-1308. doi:10.1378/chest.122.4.130.
16. Nicolini G, Ghosh-Laskar S, Shristava SK, Banerjee S, ChaudharyS, Agarwal JP, et al. Volumetric modulation arc radiotherapy withflattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: feasibility study. Int J Radiat Oncol Biol Phys. 2012; 84: 553–60.
17. Van Benthuysen L, Hales L, Podgorsak MB. Volumetric modulated arc therapy vs IMRT for the treatment of distal esophageal cancer. Med Dosim. 2011; 36: 404–9.
18. Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008; 70: 707–14.
19. Hawkins MA, Bedford JL, Warrington AP, Tait DM. Volumetric modulated arc therapy planning for distal oesophageal malignancies. Br J Radiol. 2012; 85: 44–52.